Inhibikase Therapeutics AI Stock Analysis
Inhibikase Therapeutics (IQT0) AI Stock Analysis
Inhibikase Therapeutics
(Munich:IQT0)
No summary available
Inhibikase Therapeutics (IQT0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 203.39M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- ―
- Revenue Growth
- ―
- EPS Growth
- 32.42%
- Country
- Germany
- Employees
- 35
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Inhibikase Therapeutics Business Overview & Revenue Model
Company Description
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threaten...
Inhibikase Therapeutics Earnings Call Summary
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Inhibikase Therapeutics Q2 2024 earnings call, executives highlighted several key metrics and developments. The company completed enrollment for the Phase II trial of risvodetinib in Parkinson's disease, expecting to report top-line data in November. They observed 49 adverse events and had six withdrawals from the trial. For their IkT-001Pro, a prodrug formulation aimed at pulmonary arterial hypertension (PAH), they filed an IND on August 9, 2024, with plans for a Phase IIb trial involving around 100 patients. Financially, Inhibikase reported a net loss of $5.0 million for the quarter, with R&D expenses decreasing by $1.5 million to $3.1 million, and a cash position of $7.9 million as of June 30, 2024. The company expects its cash runway to extend into December 2024, bolstered by raising $4 million in May from registered direct offering and concurrent private placement.
Inhibikase Therapeutics Risk Analysis
Inhibikase Therapeutics disclosed 82 risk factors in its most recent earnings report. Inhibikase Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskInhibikase Therapeutics Peers Comparison
Overall Rating
SRZN53Neutral
ANIX49Neutral
SPRO44Neutral
ATOS43Neutral
TCRX38.35Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | $616.07M | -0.75 | 228.00% | ― | 192.12% | -100.54% | |
| 49Neutral | $88.65M | -8.44 | -70.44% | ― | ― | 10.04% | |
| 44Neutral | $55.14M | -1.92 | -75.22% | ― | 36.15% | 38.57% | |
| 43Neutral | $19.26M | -0.52 | -117.07% | ― | ― | -10.80% | |
| 38Underperform | $9.83M | -0.17 | -140.75% | ― | -38.43% | 20.89% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:IQT0 | Inhibikase Therapeutics, Inc. | 2.50 | 0.00 | 0.00% | |
| ATOS | Atossa Therapeutics, Inc. | 1.93 | -9.52 | -83.15% | |
| ANIX | Anixa Biosciences | 2.55 | -1.80 | -41.38% | |
| SPRO | Spero Therapeutics | 0.95 | -1.43 | -60.25% | |
| SRZN | Surrozen, Inc. | 32.32 | 18.82 | 139.41% | |
| TCRX | Tscan Therapeutics, Inc. | 0.14 | -0.89 | -85.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
